Skip to main content
Top
Published in: American Journal of Clinical Dermatology 4/2002

01-06-2002 | Leading Article

Cellular and Molecular Pathophysiology of Cutaneous Drug Reactions

Authors: Werner J. Pichler, Nikhil Yawalkar, Markus Britschgi, Jan Depta, Ingrid Strasser, Simone Schmid, Petra Kuechler, Dean Naisbitt

Published in: American Journal of Clinical Dermatology | Issue 4/2002

Login to get access

Abstract

Hypersensitivity reactions to drugs can cause a variety of skin diseases like maculopapular, bullous and pustular eruptions. In recent years increasing evidence indicates the important role of T cells in these drug-induced skin diseases. Analysis of such drug-specific T cell clones has revealed that drugs can be recognized by αβ-T cell receptors, not only if bound covalently to peptides, but also if the drug binds in a rather labile way to the presenting major histocompatibility complex (MHC)-peptide. This presentation is sufficient to stimulate T cells.
In maculopapular exanthema (MPE), histopathological analysis typically shows a dominant T cell infiltration together with a vacuolar interface dermatitis. Immunohistochemical studies demonstrate the presence of cytotoxic CD4+ and to a lesser degree of CD8+ T cells, which contain perforin and granzyme B. They are close to keratinocytes that show signs of cell destruction. Expression of Fas ligand is barely detectable, suggesting that cytotoxic granule exocytosis may be the dominant pathway leading to keratinocyte cell damage. While in MPE, the killing of cells seems to be predominately mediated by CD4+ T cells, patients with bullous skin disease show a strong CD8+ T cell migration to the epidermis. This is probably due to a preferential presentation of the drug by MHC class I molecules, and a more extensive killing of cells that present drugs on MHC class I molecules. This might lead to bullous skin diseases.
In addition to the presence of cytotoxic T cells, drug-specific T cells also orchestrate the inflammatory skin reaction through the release and induction of various cytokines [i.e. interleukin (IL)-5, IL-6, tumor necrosis factor-α and interferon-γ] and chemokines (RANTES, eotaxin or IL-8). The increased expression of these mediators seems to contribute to the generation of tissue and blood eosinophilia, a hallmark of many drug-induced allergic reactions. However, in acute generalized exanthematous pustulosis (a peculiar form of drug allergy), neutrophils represent the predominant cell type within pustules, probably due to their recruitment by IL-8 secreting drug specific T cells and keratinocytes.
Literature
1.
go back to reference Hunziker T., Kunzi U.P., Braunschweig S., et al. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997; 52: 388–393PubMedCrossRef Hunziker T., Kunzi U.P., Braunschweig S., et al. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997; 52: 388–393PubMedCrossRef
2.
go back to reference Pichler W.J., Schnyder B., Zanni M., et al. Role of T cells in drug allergies. Allergy 1998; 53: 225–232PubMedCrossRef Pichler W.J., Schnyder B., Zanni M., et al. Role of T cells in drug allergies. Allergy 1998; 53: 225–232PubMedCrossRef
3.
go back to reference Hertl M., Merk H.F. Lymphocyte activation in cutaneous drug reactions. J Invest Dermatol 1995; 105: 95–98CrossRef Hertl M., Merk H.F. Lymphocyte activation in cutaneous drug reactions. J Invest Dermatol 1995; 105: 95–98CrossRef
4.
go back to reference Hari Y., Frutig K., Hurni M., et al. T cell involvement in cutaneous drug eruptions. Clin Exp Allergy 2001; 31: 1398–403PubMedCrossRef Hari Y., Frutig K., Hurni M., et al. T cell involvement in cutaneous drug eruptions. Clin Exp Allergy 2001; 31: 1398–403PubMedCrossRef
5.
go back to reference Britschgi M., Steiner U., Schmid S., et al. T cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001; 107: 1433–1441PubMedCrossRef Britschgi M., Steiner U., Schmid S., et al. T cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001; 107: 1433–1441PubMedCrossRef
6.
go back to reference Zanni M.P., Mauri-Hellweg D., Brander C., et al. Characterization of lidocaine-specific T cells. J Immunol 1997; 158: 1139–1148PubMed Zanni M.P., Mauri-Hellweg D., Brander C., et al. Characterization of lidocaine-specific T cells. J Immunol 1997; 158: 1139–1148PubMed
7.
go back to reference Schnyder B., Mauri-Hellweg D., Zanni M., et al. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human T cell clones. J Clin Invest 1997; 100: 136–141PubMedCrossRef Schnyder B., Mauri-Hellweg D., Zanni M., et al. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human T cell clones. J Clin Invest 1997; 100: 136–141PubMedCrossRef
8.
go back to reference Zanni M.P., von Greyerz S., Schnyder B., et al. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human aαβb T lymphocytes. J Clin Invest 1998; 102: 1591–1598PubMedCrossRef Zanni M.P., von Greyerz S., Schnyder B., et al. HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human aαβb T lymphocytes. J Clin Invest 1998; 102: 1591–1598PubMedCrossRef
9.
go back to reference Schnyder B., Frutig K., Mauri-Hellweg D., et al. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction. Clin Exp Allergy 1998; 28: 1412–1417PubMedCrossRef Schnyder B., Frutig K., Mauri-Hellweg D., et al. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction. Clin Exp Allergy 1998; 28: 1412–1417PubMedCrossRef
10.
go back to reference Yawalkar N., Egli F., Hari Y., et al. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 2000; 30: 847–855PubMedCrossRef Yawalkar N., Egli F., Hari Y., et al. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 2000; 30: 847–855PubMedCrossRef
11.
go back to reference Weltzien H.U., Moulin C., Martin S., et al. T cell immune response to haptens: structural models for allergic and autoimmune reactions. Toxicology 1996; 107: 141–151PubMedCrossRef Weltzien H.U., Moulin C., Martin S., et al. T cell immune response to haptens: structural models for allergic and autoimmune reactions. Toxicology 1996; 107: 141–151PubMedCrossRef
12.
go back to reference Posadas S.J., Leyva L., Torres M.J., et al. Subjects with allergic reactions to drugs show in vivo polarized patterns of cytokine expression depending on the chronology of the clinical reaction. J Allergy Clin Immunol 2000; 106: 769–776PubMedCrossRef Posadas S.J., Leyva L., Torres M.J., et al. Subjects with allergic reactions to drugs show in vivo polarized patterns of cytokine expression depending on the chronology of the clinical reaction. J Allergy Clin Immunol 2000; 106: 769–776PubMedCrossRef
13.
go back to reference Hertl M., Jugert F., Merk H.F. CD8+ dermal T cells from a sulphamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver microsomes. Br J Dermatol 1995; 132: 215–220PubMedCrossRef Hertl M., Jugert F., Merk H.F. CD8+ dermal T cells from a sulphamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver microsomes. Br J Dermatol 1995; 132: 215–220PubMedCrossRef
14.
go back to reference Kalish R.S., Askenase P.W. Molecular mechanisms of CD8+ T cell-mediated delayed hypersensitivity: implications for allergies, asthma and autoimmunity. J Allergy Clin Immunol 1999; 103: 192–199PubMedCrossRef Kalish R.S., Askenase P.W. Molecular mechanisms of CD8+ T cell-mediated delayed hypersensitivity: implications for allergies, asthma and autoimmunity. J Allergy Clin Immunol 1999; 103: 192–199PubMedCrossRef
15.
go back to reference Landsteiner K., Jacobs J. Studies on the sensitization of animals with simple chemical compounds. J Exp Med 1935; 61: 643–656PubMedCrossRef Landsteiner K., Jacobs J. Studies on the sensitization of animals with simple chemical compounds. J Exp Med 1935; 61: 643–656PubMedCrossRef
16.
go back to reference Park B.K., Pirmohamed M., Kitteringham N.R. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol 1998; 11: 969–988PubMedCrossRef Park B.K., Pirmohamed M., Kitteringham N.R. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol 1998; 11: 969–988PubMedCrossRef
17.
go back to reference Padovan E., Bauer T., Tongia M.M., et al. Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy. Eur J Immunol 1997; 27: 1303–1307PubMedCrossRef Padovan E., Bauer T., Tongia M.M., et al. Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy. Eur J Immunol 1997; 27: 1303–1307PubMedCrossRef
18.
go back to reference Brander C., Mauri-Hellweg D., Bettens F., et al. Heterogeneous T cell responses to beta-lactam-modified self-structures are observed in penicillin-allergic individuals. J Immunol 1995; 55: 2670–2678 Brander C., Mauri-Hellweg D., Bettens F., et al. Heterogeneous T cell responses to beta-lactam-modified self-structures are observed in penicillin-allergic individuals. J Immunol 1995; 55: 2670–2678
19.
go back to reference Griem P., Wulferink M., Sachs B., et al. Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol Today 1998; 19: 133–141PubMed Griem P., Wulferink M., Sachs B., et al. Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol Today 1998; 19: 133–141PubMed
20.
go back to reference Naisbitt D.J., Gordon S.F., Pirmohamed M., et al. Antigenicity and immunogenicity of sulfamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br J Pharmacol 2001; 139: 295–305CrossRef Naisbitt D.J., Gordon S.F., Pirmohamed M., et al. Antigenicity and immunogenicity of sulfamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. Br J Pharmacol 2001; 139: 295–305CrossRef
21.
go back to reference Merk H.F., Baron J., Kawakubo Y., et al. Metabolites and allergic drug reactions. Clin Exp Allergy 1998; 28: 21–24PubMedCrossRef Merk H.F., Baron J., Kawakubo Y., et al. Metabolites and allergic drug reactions. Clin Exp Allergy 1998; 28: 21–24PubMedCrossRef
22.
go back to reference Schneider C.H., de Weck A.L. A new chemical spectrum of penicillin allergy: the direct reaction of penicillin with epsilon-amino-groups. Nature 1965; 208: 57–59PubMedCrossRef Schneider C.H., de Weck A.L. A new chemical spectrum of penicillin allergy: the direct reaction of penicillin with epsilon-amino-groups. Nature 1965; 208: 57–59PubMedCrossRef
23.
go back to reference Cribb A.E., Spielberg S.P. Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin Pharmacol Ther 1992; 51: 522–526PubMedCrossRef Cribb A.E., Spielberg S.P. Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin Pharmacol Ther 1992; 51: 522–526PubMedCrossRef
24.
go back to reference Reilly T.P., Lash L.H., Doll M.A., et al. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Invest Dermatol 2000; 114: 1164–1173PubMedCrossRef Reilly T.P., Lash L.H., Doll M.A., et al. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Invest Dermatol 2000; 114: 1164–1173PubMedCrossRef
25.
go back to reference von Greyerz S., Zanni M., Frutig K., et al. Interaction of sulfonamide-derivatives with the TCR of sulfamethoxazole specific αβ+ T cell clones. J Immunol 1999; 162: 595–602 von Greyerz S., Zanni M., Frutig K., et al. Interaction of sulfonamide-derivatives with the TCR of sulfamethoxazole specific αβ+ T cell clones. J Immunol 1999; 162: 595–602
26.
go back to reference Zanni M.P., von Greyerz S., Schnyder B., et al. HLA-unrestricted presentation of lidocaine by HLA-DR molecules to specific αβ+ T cell clones. Immunol Int 1998; 10: 507–515CrossRef Zanni M.P., von Greyerz S., Schnyder B., et al. HLA-unrestricted presentation of lidocaine by HLA-DR molecules to specific αβ+ T cell clones. Immunol Int 1998; 10: 507–515CrossRef
27.
go back to reference Schnyder B., Burkhart C., Schnyder-Frutig K., et al. Recognition of sulfamethoxazole and its reactive metabolites by drug specific T cells from allergic individuals. J Immunol 2000; 164: 6647–6654PubMed Schnyder B., Burkhart C., Schnyder-Frutig K., et al. Recognition of sulfamethoxazole and its reactive metabolites by drug specific T cells from allergic individuals. J Immunol 2000; 164: 6647–6654PubMed
28.
go back to reference von Greyerz S, Burkhart C., Pichler W.J. Molecular basis of drug recognition by specific T cell receptors. Int Arch Allergy Immunol 1999; 119: 173–180CrossRef von Greyerz S, Burkhart C., Pichler W.J. Molecular basis of drug recognition by specific T cell receptors. Int Arch Allergy Immunol 1999; 119: 173–180CrossRef
29.
go back to reference Burkhart C., von Greyerz S., Depta J.P., et al. Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells. Br J Pharmacol 2001; 132: 623–630PubMedCrossRef Burkhart C., von Greyerz S., Depta J.P., et al. Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells. Br J Pharmacol 2001; 132: 623–630PubMedCrossRef
30.
go back to reference Pichler W.J. Predictive drug allergy testing, an alternative viewpoint. Toxicology 2001; 158: 31–41PubMedCrossRef Pichler W.J. Predictive drug allergy testing, an alternative viewpoint. Toxicology 2001; 158: 31–41PubMedCrossRef
31.
go back to reference Heller H.M. Adverse cutaneous drug reactions in patients with human immunodeficiency virus-1 infection. Clin Dermatol 2000; 18: 485–489PubMedCrossRef Heller H.M. Adverse cutaneous drug reactions in patients with human immunodeficiency virus-1 infection. Clin Dermatol 2000; 18: 485–489PubMedCrossRef
32.
go back to reference Suzuki Y., Inage R., Aono T., et al. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol 1996; 134: 1108–1112CrossRef Suzuki Y., Inage R., Aono T., et al. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol 1996; 134: 1108–1112CrossRef
33.
go back to reference Antonen J.A., Markula K.P., Pertovaara M.I., et al. Adverse drug reactions in Sjögren syndrome: frequent allergic reactions and a specific trimethoprim-associated systemic reaction. Scand J Rheumatol 1999; 28: 157–159PubMedCrossRef Antonen J.A., Markula K.P., Pertovaara M.I., et al. Adverse drug reactions in Sjögren syndrome: frequent allergic reactions and a specific trimethoprim-associated systemic reaction. Scand J Rheumatol 1999; 28: 157–159PubMedCrossRef
34.
go back to reference Gallucci S., Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001; 13: 114–119PubMedCrossRef Gallucci S., Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001; 13: 114–119PubMedCrossRef
35.
go back to reference Crowson A.N., Magro C.M. Recent advances in the pathology of cutaneous drug eruptions. Dermatol Clin 1999; 17: 537–560PubMedCrossRef Crowson A.N., Magro C.M. Recent advances in the pathology of cutaneous drug eruptions. Dermatol Clin 1999; 17: 537–560PubMedCrossRef
36.
go back to reference Fellner M.J., Prutkin L. Morbilliform eruptions caused by penicillin: a study by electron microscopy and immunologic tests. J Invest Dermatol 1970; 55: 390–395PubMedCrossRef Fellner M.J., Prutkin L. Morbilliform eruptions caused by penicillin: a study by electron microscopy and immunologic tests. J Invest Dermatol 1970; 55: 390–395PubMedCrossRef
37.
go back to reference Yawalkar N., Shrikhande M., Hari Y., et al. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 2000; 106: 1171–1176PubMedCrossRef Yawalkar N., Shrikhande M., Hari Y., et al. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 2000; 106: 1171–1176PubMedCrossRef
38.
go back to reference Carr A., Vasak E., Munro V., et al. Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection. Clin Exp Immunol 1994; 97: 260–265PubMedCrossRef Carr A., Vasak E., Munro V., et al. Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection. Clin Exp Immunol 1994; 97: 260–265PubMedCrossRef
39.
go back to reference Barbaud A.M., Bene M.C., Reichert-Penetrat S., et al. Immunocompetent cells and adhesion molecules in 14 cases of cutaneous drug reactions induced with the use of antibiotics. Arch Dermatol 1998; 134: 1040–1041PubMedCrossRef Barbaud A.M., Bene M.C., Reichert-Penetrat S., et al. Immunocompetent cells and adhesion molecules in 14 cases of cutaneous drug reactions induced with the use of antibiotics. Arch Dermatol 1998; 134: 1040–1041PubMedCrossRef
40.
go back to reference Barbaud A.M., Bene M.C., Schmutz J.L., et al. Role of delayed cellular hypersensitivity and adhesion molecules in amoxicillin-induced morbilliform rashes. Arch Dermatol 1997; 133: 481–486PubMedCrossRef Barbaud A.M., Bene M.C., Schmutz J.L., et al. Role of delayed cellular hypersensitivity and adhesion molecules in amoxicillin-induced morbilliform rashes. Arch Dermatol 1997; 133: 481–486PubMedCrossRef
41.
go back to reference Blanca M., Posadas S., Torres M.J., et al. Expression of the skin-homing receptor in peripheral blood lymphocytes from subjects with non immediate cutaneous allergic drug reactions. Allergy 2000; 55: 998–1004PubMedCrossRef Blanca M., Posadas S., Torres M.J., et al. Expression of the skin-homing receptor in peripheral blood lymphocytes from subjects with non immediate cutaneous allergic drug reactions. Allergy 2000; 55: 998–1004PubMedCrossRef
42.
go back to reference Stepp S.E., Mathew P.A., Bennett M., et al. Perforin: more than just an effector molecule. Immunol Today 2000; 21: 254–256PubMedCrossRef Stepp S.E., Mathew P.A., Bennett M., et al. Perforin: more than just an effector molecule. Immunol Today 2000; 21: 254–256PubMedCrossRef
43.
go back to reference Yawalkar N., Hari Y., Frutig K., et al. T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. J Invest Dermatol 2000; 115: 647–652PubMedCrossRef Yawalkar N., Hari Y., Frutig K., et al. T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. J Invest Dermatol 2000; 115: 647–652PubMedCrossRef
44.
go back to reference Behrendt C., Gollnick H., Bonnekoh B. Up-regulated perforin expression of CD8+ blood lymphocytes in generalized non-anaphylactic drug eruptions and exacerbated psoriasis. Eur J Dermatol 2000; 10: 365–369PubMed Behrendt C., Gollnick H., Bonnekoh B. Up-regulated perforin expression of CD8+ blood lymphocytes in generalized non-anaphylactic drug eruptions and exacerbated psoriasis. Eur J Dermatol 2000; 10: 365–369PubMed
45.
go back to reference Viard I., Wehrli P., Bullani R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490–493PubMedCrossRef Viard I., Wehrli P., Bullani R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490–493PubMedCrossRef
46.
go back to reference Brugnolo F., Annunziato F., Sampognaro S., et al. Highly Th2-skewed cytokine profile of beta-lactam-specific T cells from nonatopic subjects with adverse drug reactions. J Immunol 1999; 163: 1053–1059PubMed Brugnolo F., Annunziato F., Sampognaro S., et al. Highly Th2-skewed cytokine profile of beta-lactam-specific T cells from nonatopic subjects with adverse drug reactions. J Immunol 1999; 163: 1053–1059PubMed
47.
go back to reference Hari Y., Urwyler A., Hurni M., et al. Distinct serum cytokine levels in drug or measles induced exanthema. Int Arch Allergy Immunol 1999; 120: 225–229PubMedCrossRef Hari Y., Urwyler A., Hurni M., et al. Distinct serum cytokine levels in drug or measles induced exanthema. Int Arch Allergy Immunol 1999; 120: 225–229PubMedCrossRef
48.
go back to reference Choquet-Kastylevsky G., Intrator L., Chenal C., et al. Increased levels of Interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol 1998; 139: 1026–1032PubMedCrossRef Choquet-Kastylevsky G., Intrator L., Chenal C., et al. Increased levels of Interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol 1998; 139: 1026–1032PubMedCrossRef
49.
go back to reference Osawa J., Kitamura K., Saito S., et al. Immunohistochemical study of graft-versushost reaction (GVHR)-type drug eruptions. J Dermatol 1994; 21: 25–30PubMed Osawa J., Kitamura K., Saito S., et al. Immunohistochemical study of graft-versushost reaction (GVHR)-type drug eruptions. J Dermatol 1994; 21: 25–30PubMed
50.
go back to reference Gerber B.O., Zanni M.P., Uguccioni M., et al. Functional expression of the eotaxin receptor, CCR3, in T lymphocytes co-localizing with eosinophils. Curr Biol 1997; 7: 836–843PubMedCrossRef Gerber B.O., Zanni M.P., Uguccioni M., et al. Functional expression of the eotaxin receptor, CCR3, in T lymphocytes co-localizing with eosinophils. Curr Biol 1997; 7: 836–843PubMedCrossRef
51.
go back to reference Garcia-Doval I., LeCleach L., Bocquet H., et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136: 323–327PubMedCrossRef Garcia-Doval I., LeCleach L., Bocquet H., et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136: 323–327PubMedCrossRef
52.
go back to reference Fam A.G., Dunne S.M., Iazzetta J., et al. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 2001; 44: 231–238PubMedCrossRef Fam A.G., Dunne S.M., Iazzetta J., et al. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 2001; 44: 231–238PubMedCrossRef
53.
go back to reference Le Cleach L, Delaaire S., Boumsell L., et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 2000; 119: 225–230PubMedCrossRef Le Cleach L, Delaaire S., Boumsell L., et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 2000; 119: 225–230PubMedCrossRef
54.
go back to reference Nassif A., Bensussan A., Dorothée G., et al. Drug-specific cytotoxic T lymphocytes in the skin lesions of a patient with toxic epidermal necrolysis [abstract]. Allergologie 2001; 24: 222 Nassif A., Bensussan A., Dorothée G., et al. Drug-specific cytotoxic T lymphocytes in the skin lesions of a patient with toxic epidermal necrolysis [abstract]. Allergologie 2001; 24: 222
55.
go back to reference Ryo K., Kamogawa Y., Ikeda I., et al. Significance of Fas antigen mediated apoptosis in human hepatic failure. Am J Gastroenterol 2000; 95: 2047–2055PubMedCrossRef Ryo K., Kamogawa Y., Ikeda I., et al. Significance of Fas antigen mediated apoptosis in human hepatic failure. Am J Gastroenterol 2000; 95: 2047–2055PubMedCrossRef
56.
go back to reference Pereira S., Almeida J., Silva A.O., et al. Fatal liver necrosis due to allopurinol. Acta Med Port 1998; 11: 1141–1144PubMed Pereira S., Almeida J., Silva A.O., et al. Fatal liver necrosis due to allopurinol. Acta Med Port 1998; 11: 1141–1144PubMed
57.
go back to reference Bachot N., Revuz J., Roujeau J.C. Are intravenous immunoglobulins the treatment of Stevens-Johnson syndrome or toxic epidermal necrolysis? [abstract]. Allergologie 2001; 24: 214 Bachot N., Revuz J., Roujeau J.C. Are intravenous immunoglobulins the treatment of Stevens-Johnson syndrome or toxic epidermal necrolysis? [abstract]. Allergologie 2001; 24: 214
58.
go back to reference Roujeau J., Bioulac-Sage P., Bourseau C. Acute generalized exanthematous pustulosis: analysis of 63 cases. Arch Dermatol 1991; 127: 1333–1338PubMedCrossRef Roujeau J., Bioulac-Sage P., Bourseau C. Acute generalized exanthematous pustulosis: analysis of 63 cases. Arch Dermatol 1991; 127: 1333–1338PubMedCrossRef
59.
go back to reference Wolkenstein P., Chosidow O., Fléchet M.L., et al. Patch-testing in severe cutaneous adverse drug reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996; 35: 234–236PubMedCrossRef Wolkenstein P., Chosidow O., Fléchet M.L., et al. Patch-testing in severe cutaneous adverse drug reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996; 35: 234–236PubMedCrossRef
60.
go back to reference Knowles S.R., Shapiro L.E., Shear N.H. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999; 21: 489–501PubMedCrossRef Knowles S.R., Shapiro L.E., Shear N.H. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf 1999; 21: 489–501PubMedCrossRef
61.
go back to reference Mauri-Hellweg D., Bettens F., Mauri D., et al. Activation of drug specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin and carbamazepine. J Immunol 1995; 155: 462–472PubMed Mauri-Hellweg D., Bettens F., Mauri D., et al. Activation of drug specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin and carbamazepine. J Immunol 1995; 155: 462–472PubMed
62.
go back to reference Pichler W.J., Zanni M., Schnyder B., et al. Characterization of drug-specific T cells. In: Oehling A.K., Huerta Lopez JG, editors. Progress in allergy and clinical immunology. Seattle (WA): Hogrefe & Huber, 1997: 368–371 Pichler W.J., Zanni M., Schnyder B., et al. Characterization of drug-specific T cells. In: Oehling A.K., Huerta Lopez JG, editors. Progress in allergy and clinical immunology. Seattle (WA): Hogrefe & Huber, 1997: 368–371
63.
go back to reference Descamps V., Valance A., Edlinger C., et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001; 137: 301–304PubMed Descamps V., Valance A., Edlinger C., et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001; 137: 301–304PubMed
64.
go back to reference Hashimoto K., Toyama M. HHV-6 associated drug eruptions (HADE) [abstract]. Allergologie 2001; 24: 219 Hashimoto K., Toyama M. HHV-6 associated drug eruptions (HADE) [abstract]. Allergologie 2001; 24: 219
65.
go back to reference Arakawa M., Kakuto Y., Ichikawa K., et al. Allopurinol hypersensitivity syndrome associated with systemic cytomegalovirus infection and systemic bacteremia. Intern Med 2001; 40: 331–335PubMedCrossRef Arakawa M., Kakuto Y., Ichikawa K., et al. Allopurinol hypersensitivity syndrome associated with systemic cytomegalovirus infection and systemic bacteremia. Intern Med 2001; 40: 331–335PubMedCrossRef
66.
go back to reference Pichler W.J. Drug allergy: relationship between immunogenicity and clinical symptoms. Allergy 1999; 54 Suppl. 58: 5–7PubMedCrossRef Pichler W.J. Drug allergy: relationship between immunogenicity and clinical symptoms. Allergy 1999; 54 Suppl. 58: 5–7PubMedCrossRef
Metadata
Title
Cellular and Molecular Pathophysiology of Cutaneous Drug Reactions
Authors
Werner J. Pichler
Nikhil Yawalkar
Markus Britschgi
Jan Depta
Ingrid Strasser
Simone Schmid
Petra Kuechler
Dean Naisbitt
Publication date
01-06-2002
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 4/2002
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200203040-00001

Other articles of this Issue 4/2002

American Journal of Clinical Dermatology 4/2002 Go to the issue

Therapy in Practice

Basal Cell Carcinoma

Therapy in Practice

Photosensitivity Disorders